Search

Your search keyword '"Tomás, J"' showing total 6 results
Start Over Author "Tomás, J" Journal blood
6 results on '"Tomás, J"'

1. The cellular origin and malignant transformation of Waldenström macroglobulinemia

Author

Paiva, Bruno, Corchete, Luis A., Vidriales, Maria-Belen, García-Sanz, Ramón, Perez, Jose J., Aires-Mejia, Irene, Sanchez, Maria-Luz, Barcena, Paloma, Alignani, Diego, Jimenez, Cristina, Sarasquete, Maria-Eugenia, Mateos, María-Victoria, Ocio, Enrique M., Puig, Noemi, Escalante, Fernando, Hernández, José, Cuello, Rebeca, García de Coca, Alfonso, Sierra, Magdalena, Montes, Maria-Carmen, González-López, Tomás J., Galende, Josefina, Bárez, Abelardo, Alonso, José, Pardal, Emilia, Orfao, Alberto, Gutierrez, Norma C., and San Miguel, Jesús F.

Published
2015
Full Text
View/download PDF

3. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

Author

Paiva, Bruno, Martinez-Lopez, Joaquin, Corchete, Luis A., Sanchez-Vega, Beatriz, Rapado, Inmaculada, Puig, Noemi, Barrio, Santiago, Sanchez, Maria-Luz, Alignani, Diego, Lasa, Marta, García de Coca, Alfonso, Pardal, Emilia, Oriol, Alberto, Garcia, Maria-Esther Gonzalez, Escalante, Fernando, González-López, Tomás J., Palomera, Luis, Alonso, José, Prosper, Felipe, Orfao, Alberto, Vidriales, Maria-Belen, Mateos, María-Victoria, Lahuerta, Juan-Jose, Gutierrez, Norma C., and San Miguel, Jesús F.

Published
2016
Full Text
View/download PDF

4. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party

Author

Carreras, E, Bertz, H, Arcese, W, Vernant, J, Tomás, J, Hagglund, H, Bandini, G, Esperou, H, Russell, J, de la Rubia, J, Di Girolamo, G, Demuynck, H, Hartmann, O, Clausen, J, Ruutu, T, Leblond, V, Iriondo, A, Bosi, A, Ben Bassat, I, Koza, V, Gratwohl, A, and Apperley, J

Subjects
Adult, Transplantation Conditioning, Incidence, Hematopoietic Stem Cell Transplantation, Hepatic Veno-Occlusive Disease, Middle Aged, Humans, Child, Europe, Prospective Studies, Cohort Studies, Treatment Outcome, Bone Marrow Transplantation, Settore MED/15 - Malattie del Sangue
Abstract

To determine the incidence and outcome of hepatic veno-occlusive disease (VOD) after blood or marrow transplantation (BMT), we prospectively evaluated all consecutive patients receiving a BMT during a 6-month period in participating EBMT centers. All of them were evaluated for occurrence of VOD according to previously defined clinical criteria. The clinical course, outcome, value of prophylactic and therapeutic interventions, and the influence of previously described risk factors were analyzed. During the study period, 1,652 BMT were performed in 73 centers. VOD was diagnosed in 87 patients (5.3%; 95% confidence interval [CI], 4.2% to 6.4%). Fifty-six of 631 allogeneic BMT (8.9%) and 31 of 1,010 autologous BMT (3.1%) developed this complication (P.0001). VOD was classified as mild in 7 (8%), moderate in 56 (64.4%), and severe in 24 (27.6%) cases. Sixteen patients died of VOD (corresponding to 1% of the whole series, 18.4% of VOD patients, and 66.7% of severe VOD). The use of unfractionated heparin did not significantly decrease the incidence of VOD. Independent variables associated with an increased risk of VOD were allogeneic BMT (relative risk [RR], 2.8; P.001), pre-BMT elevation of serum aspartate aminotransferase (RR, 2.4; P =.001), high-dose cytoreductive therapy (RR, 2.3; P =.003), Karnofsky performance score less than 90% (RR, 2.7; P =.006), and prior abdominal radiation (RR, 2.9; P =.03). In conclusion, this prospective study shows that (1) the incidence of VOD is lower than that reported in smaller studies from single centers, (2) about one fourth of cases of VOD progress to severe disease, (3) main risk factors have a major impact on incidence of VOD, and (4) the use of prophylactic unfractionated heparin does not seem to reduce the incidence of VOD.

Published
1998

5. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study.

Author

Rodriguez-Iñigo E, Tomás JF, Gómez-García de Soria V, Bartolomé J, Pinilla I, Amaro MJ, Carreño V, and Fernández-Rañada JM

Subjects
Acute Disease, Adolescent, Adult, Biomarkers, Cause of Death, Chronic Disease, Female, Follow-Up Studies, Hematologic Diseases complications, Hematologic Diseases therapy, Hepatitis Antibodies blood, Hepatitis C diagnosis, Hepatitis C epidemiology, Hepatitis, Viral, Human diagnosis, Hepatitis, Viral, Human epidemiology, Humans, Liver Diseases epidemiology, Liver Diseases virology, Liver Function Tests, Male, Middle Aged, Prevalence, Prospective Studies, RNA, Viral blood, Time Factors, Transfusion Reaction, Transplantation, Homologous adverse effects, Bone Marrow Transplantation adverse effects, Flaviviridae immunology, Flaviviridae isolation & purification, Hepatitis C complications, Hepatitis, Viral, Human complications, Liver Diseases etiology
Abstract

Acute and chronic liver dysfunction is common after allogeneic bone marrow transplantation (BMT). Although toxicity, graft versus-host disease (GVHD), and viral infections are the major causes, etiologic diagnosis is difficult and often remains unknown. We conducted a prospective study to establish the role of the infection with both the hepatitis C virus (HCV) and the recently discovered hepatitis G virus (HGV) in liver dysfunction after BMT. From January 1994 to December 1995, 59 patients who had undergone an allogeneic BMT at our institution were enrolled in the study. HGV-RNA was identified in serum by nested polymerase chain reaction (PCR), and HCV was studied by the presence of second generation enzyme-linked immunosorbent assay (ELISA)-antibodies and HCV-RNA by nested PCR. HGV-RNA was detected in 25 patients (42%) (before BMT in 18 and after BMT in 7). HCV-RNA was present in 12 patients (20%) (before BMT in 11 and after BMT in one). The presence of HCV-RNA and HGV-RNA was clearly associated with a previous history of blood transfusions. No significant association was found between viral infection and acute liver toxicity. Some degree of liver dysfunction was present 6 months after BMT in 25 of 40 evaluable patients (62%). Long-term liver dysfunction was more common among patients infected with HCV alone (3 of 4) or with both HCV and HGV (3 of 3) than in those infected with either HGV alone (eight of 13) or with no virus infection (10 of 20). We found a high prevalence of HGV infection in our BMT population. However, no role for HGV in liver disease could be established in this study, and the relationship between HGV infection and liver dysfunction requires further clarification.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results